-
Integrase Inhibitors Do Not Increase Cardiovascular Event Risk in HIV Patients
This article discusses a significant study presented at the 19th European AIDS Conference (EACS 2023), held in Warsaw, Poland, from October 18-20, 2023. Professor Bernard Surial from the University of Bern in Switzerland shared the results of an international cohort study, which revealed that the use of integrase strand transfer inhibitors (INSTIs) in the treatment…
-
ESMO Live Update | Dr. Girard Analyzes PAPILLON trial: Opening New Doors for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Advanced NSCLC
Based on the results of the PAPILLON trial, presented at Presidential Symposium 1 at the ESMO Congress 2023 (Madrid, Spain, 20-24 October), a dual-specificity EGFR/MET-directed monoclonal antibody has the potential…
-
Dr. Jiayu Wang: Revisiting International Conferences with Promising Efficacy Data – Domestic Innovative CDK4/6 Inhibitor Birociclib as a New Choice for HR+/HER2-MBC Treatment
Editor’s Note: During the 2023 European Society for Medical Oncology (ESMO) Annual Meeting, a Phase II multi-center clinical trial’s results, led by Academician Xu Binghe and his team from the…
-
ESMO 2023 | SKB264 (TROP2-ADC) Shows Promise in the Treatment of HR+/HER2- Metastatic Breast Cancer, Advancing in Multiple Cancer Types
TROP2 (Trophoblast Cell-Surface Antigen 2) is highly expressed in various solid tumors, making it a hot target in the field of oncology. The development of antibody-drug conjugates (ADCs) targeting this…
-
2023 ESMO Congress Reveals YOUNGBC-21 Study Results
Editor’s note: HER2-positive metastatic breast cancer (HER2+ MBC) has seen the emergence of several new drugs, but the combination of Pyrotinib with dual targeting therapy remains the preferred first-line option.…
-
Dr. Tao Sun & Dr. Yehui Shi: Eribulin Combination Therapy Shines for Breast Cancer Patients, Providing More Treatment Options
Editor’s Note: Breast cancer has become the most common malignant tumor globally, with approximately 30% to 40% of early-stage breast cancer patients ultimately progressing to advanced breast cancer.At this year’s…
-
Dr. Liang Han: Phase III MATTERHORN Study Shows Significant Improvement in pCR for Neoadjuvant Treatment of Gastric Cancer with Pembrolizumab
Editor’s Note:This 2023 ESMO Annual Meeting, in the field of gastric cancer, the global Phase III MATTERHORN study of the anti-PD-L1 antibody pembrolizumab in combination with the FLOT regimen for…
-
ESMO Exclusive Interview | Professor Huiyan Luo : Significant Efficacy of the Combination of Anti-PD-L1/TGF-βRII Dual-Target Antibody SHR-1701 with Bevacizumab in the Treatment of Advanced Solid Tumors
Editor’s Note: The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place from October 20th to 24th in Madrid, Spain. The Oncology Insights Reporting Team delved deep into…
Connecting Medical Expertise through Media